Good MorningThe market heaved a sigh of relief after Fed president Raphael Bostic said the committee could probably stick with quarter-point interest rate hikes. The news is contrary to a renewed belief the Fed could increase the pace to 50 bps per meeting, but investors should not be sanguine. The news does not suggest that inflation has been tamed or the Fed was anywhere near through with raising rates.
Regardless of the Fed's next move, the outlook for S&P 500 earnings continues to decline, and that is a weight the market can't bear forever. Sooner or later, the market will give up all hope for earnings growth in 2023 and the market decline will start in earnest. At best, the S&P 500 is range bound but headed toward the bottom of that range. The following week could be trying for the market with little to sustain the rebound regarding economic data or earnings reports. Featured: Forbes mag says this strategy "like finding money in the street" (Tradewins) 
|
Tech | | | After sweeping through battles in statehouses across the country, the war against ESG investing is heating up in Congress.
The Senate voted Wednesday to overturn a Labor Department rule allowing retirement plans to consider environmental, social and governance factors when making inve... Read the Full Story |
|
From Our PartnersMaking profits in the stock market depends on making your entry at the right time. The time is NOW to get into A.I. Artificial Intelligence is turning into one of the most popular trends this year, and it has only just begun.
(**By clicking the link you are subscribing to the The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here)
| | | | Go HERE to Reveal Which Stock These Are |
|
Markets | | |
High-growth cloud computing firm Snowflake (NYSE: SNOW) reported earnings after the close on Wednesday, and the results were not what investors were hoping for. The stock dropped by 11% following the earnings report, which showed disappointing guidance.
Snowflake is one of the fastest-growing tec... Read the Full Story |
|
Stocks | | | Stocks are rising Monday, clawing back some of their losses from Wall Street’s worst week since early December.
The S&P 500 was 0.6% higher in afternoon trading and on pace for just its second gain in the last seven days. The Dow Jones Industrial Average was up 146 points, or 0.5%... Read the Full Story |
|
From Our PartnersAs tensions mount over Taiwan, China is engaging in a stealth war against the U.S. that could cripple our military production. China controls up to 90% of the critical elements needed to secure our national defense. But new mineral discoveries in America could end our dependence on China. One exploration company is well-positioned to advance U.S. national security interests. | | | | Click here for this rare investment opportunity |
|
Stocks | | |
It’s too soon to call October 13th the low for U.S. stocks. With the Federal Reserve steadfast in its view of higher rates for longer, equity valuations may not have yet reached the basement.
The good news is that the stock market has distanced itself from its 2022 bottom. And with some Fed... Read the Full Story |
|
Stocks | | | Stocks steadied themselves Monday following Wall Street's worst week since early December.
The S&P 500 rose 12.20 points, or 0.3% to 3,982.24 for just its second gain in the last seven days. The Dow Jones Industrial Average gained 72.17, or 0.2%, to 32,889.09, while the Nasdaq com... Read the Full Story |
|
|
Markets | | |
If you own a portfolio of dividend stocks, you might wonder how to earn more income from your investments.
You can follow one simple strategy to unlock more income from your portfolio. This strategy involves limited risk and may also lead to appreciable upside returns.
Let’s cover th... Read the Full Story |
|
Markets | | |
Investors who’ve shied away from Hormel (NYSE: HRL) may want to take a 2nd look. The Q1 results and guidance for 2023 have sparked a pullback in prices that should result in another stunning rebound. This stock is trading at a 2-year low which marks the bottom of the post-pandemic trading ra... Read the Full Story |
|
Stocks | | | Stocks are opening higher, clawing back some of the losses from their worst week since early December. The S&P 500 rose 0.8% early Monday and is on pace for just its second gain in the last seven days. The Dow and the Nasdaq also rose. Stocks have struggled in February after a strong start to th... Read the Full Story |
|
Markets | | | Wall Street pointed toward gains before the opening bell Monday after last week's rout and ahead of another full slate of corporate earnings this week.
Futures for the benchmark S&P 500 rose 0.5% and futures for the Dow Jones industrials moved 0.4% higher.
Last week... Read the Full Story |
|
Stocks | | |
Oil tankers have been on an uptrend for the past year, with no real signs of slowing down. In one of the latest developments, Nordic American Tanker Ltd. (NYSE: NAT) on February 27, boosted its shareholder payout by 200%, from $0.05 a share to $0.15, according to MarketBeat data on dividend increa... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. | | View Today's Stock Pick |
|
